We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Identification of serum CCL15 in hepatocellular carcinoma.
- Authors
Li Y; Wu J; Zhang W; Zhang N; Guo H; Li, Y; Wu, J; Zhang, W; Zhang, N; Guo, H
- Abstract
<bold>Background: </bold>Early serum detection is of critical importance to improve the therapy for hepatocellular carcinoma (HCC), one of the most deadly cancers. Hepatitis infection is a leading cause of HCC.<bold>Methods: </bold>In the present study, we collected total serum samples with informed consent from 80 HCC patients with HBV (+)/cirrhosis (+), 80 patients with benign diseases (50 liver cirrhosis patients and 30 HBV-infected patients) and 60 healthy controls. Analysis was by using surface-enhanced laser desorption/ionisation-time-of-flight mass spectroscopy (SELDI-TOF-MS) to find new serum markers of HCC. SELDI peaks were isolated by SDS-PAGE, identified by LC-MS/MS and validated by immunohistochemistry (IHC) in liver tissues. Migration and invasion assay were performed to test the ability of cell migration and invasion in vitro.<bold>Results: </bold>SELDI-TOF-MS revealed a band at 7777 M/Z in the serum samples from HCC patients but not from healthy controls or patients with benign diseases. The protein (7777.27 M/Z) in the proteomic signature was identified as C-C motif chemokine 15 (CCL15) by peptide mass fingerprinting. A significant increase in serum CCL15 was detected in HCC patients. Functional analysis showed that HCC cell expressed CCL15, which in turn promoted HCC cell migration and invasion.<bold>Conclusion: </bold>CCL15 may be a specific proteomic biomarker of HCC, which has an important role in tumorigenesis and tumour invasion.
- Publication
British Journal of Cancer, 2013, Vol 108, Issue 1, p99
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/bjc.2012.494